Neuroimaging in the Diagnosis of Alzheimer's Disease and Dementia
The DN convened this exploratory meeting in conjunction with the Center for Medicaid and Medicare Services to explore the status of various neuroimaging technologies (magnetic resonance imaging, positron emission tomography, and single photon emission spectroscopy) in the diagnosis of mild cognitive impairment and Alzheimer's disease. The sensitivity/specificity of each were compared at various stages of illness and cost versus benefit over clinical diagnosis alone, given the current state of therapeutics. Also discussed was how these parameters may change with the introduction of a disease-modifying drug.
Dr. John Hsiao, DN